OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado. Show more
6707 Winchester Circle, Boulder, CO, 80301, United States
Start AI Chat
Market Cap
33.19M
52 Wk Range
$1.70 - $5.60
Previous Close
$2.45
Open
$2.45
Volume
103,109
Day Range
$2.45 - $2.60
Enterprise Value
-44.67M
Cash
70.33M
Avg Qtr Burn
-13.04M
Insider Ownership
1.79%
Institutional Own.
88.91%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
OKI-219 +/- Fulvestrant or Trastuzumab Details Breast cancer, Cancer | Phase 1 Data readout | |
Mavodelpar (REN001) Details long-chain fatty acid oxidation disorders | Failed Discontinued | |
Mavodelpar (REN001) Details primary mitochondrial myopathies | Failed Discontinued | |
Failed Discontinued |
